INTRODUCTION: This prospective observational study examined the adherence to published European guidelines on erythropoiesis-stimulating agents (ESAs) and the pattern of use and effect of darbepoetin alfa (DA) 500 microg once every 3 weeks (Q3W) for the treatment of chemotherapy-induced anaemia (CIA). MATERIALS AND METHODS: A total of 293 patients were included (263 solid tumour, 30 haematologic malignancy). Their mean age was 63 years, 51% were male, 57% had platinum-based chemotherapy. DA was started at a haemoglobin (Hb) level between 9 and 11 g/dL in 82% of patients. RESULTS AND DISCUSSION: In an analysis correcting for transfusions, 55% of patients achieved > or =2 g/dL increase in Hb, and a Hb level of >11 g/dL was reached in 81%. Transfusion rate was 27%. Most patients (70%) were treated in a Q3W chemotherapy, and planned synchronisation of chemotherapy and Q3W DA could be maintained in 76%. CONCLUSION: Adherence to European guidelines for DA treatment was good, and Q3W DA treatment was in synchronisation with Q3W chemotherapy in the majority of the patients, thereby reproducing the findings of a recent phase III study.
INTRODUCTION: This prospective observational study examined the adherence to published European guidelines on erythropoiesis-stimulating agents (ESAs) and the pattern of use and effect of darbepoetin alfa (DA) 500 microg once every 3 weeks (Q3W) for the treatment of chemotherapy-induced anaemia (CIA). MATERIALS AND METHODS: A total of 293 patients were included (263 solid tumour, 30 haematologic malignancy). Their mean age was 63 years, 51% were male, 57% had platinum-based chemotherapy. DA was started at a haemoglobin (Hb) level between 9 and 11 g/dL in 82% of patients. RESULTS AND DISCUSSION: In an analysis correcting for transfusions, 55% of patients achieved > or =2 g/dL increase in Hb, and a Hb level of >11 g/dL was reached in 81%. Transfusion rate was 27%. Most patients (70%) were treated in a Q3W chemotherapy, and planned synchronisation of chemotherapy and Q3W DA could be maintained in 76%. CONCLUSION: Adherence to European guidelines for DA treatment was good, and Q3W DA treatment was in synchronisation with Q3W chemotherapy in the majority of the patients, thereby reproducing the findings of a recent phase III study.
Authors: John Glaspy; David Henry; Ravi Patel; Simon Tchekmedyian; Steve Applebaum; Donald Berdeaux; Richard Lloyd; Russell Berg; Matt Austin; Greg Rossi Journal: Eur J Cancer Date: 2005-04-08 Impact factor: 9.162
Authors: Julia Bohlius; Simon Langensiepen; Guido Schwarzer; Jerome Seidenfeld; Margaret Piper; Charles Bennett; Andreas Engert Journal: J Natl Cancer Inst Date: 2005-04-06 Impact factor: 13.506
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Julia Bohlius; Jayne Wilson; Jerome Seidenfeld; Margaret Piper; Guido Schwarzer; Josie Sandercock; Sven Trelle; Olaf Weingart; Sue Bayliss; Benjamin Djulbegovic; Charles L Bennett; Simon Langensiepen; Chris Hyde; Andreas Engert Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: C Bokemeyer; M S Aapro; A Courdi; J Foubert; H Link; A Osterborg; L Repetto; P Soubeyran Journal: Eur J Cancer Date: 2004-10 Impact factor: 9.162
Authors: Jean-Luc Canon; Johan Vansteenkiste; György Bodoky; M Victoria Mateos; Laurent Bastit; Irene Ferreira; Greg Rossi; Rafael G Amado Journal: J Natl Cancer Inst Date: 2006-02-15 Impact factor: 13.506
Authors: Johan Vansteenkiste; Robert Pirker; Bartomeu Massuti; Fernando Barata; Albert Font; Michael Fiegl; Salvatore Siena; Jenni Gateley; Dianne Tomita; Alan B Colowick; Jaromir Musil Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506